


.Outset


Reimagining the future of dialysis

Outset Medical
**2022 ESG Report
Supplement**




Independence

- Independent 7
- Management 1




Tenure

- < 1 year 1
- 1-4 years 5
- 5+ years 2



Age

- < 60 years old 3
- 60+ years old 5



Gender diversity

- Women 4
- Men 4



Racial or ethnic diversity

- Diverse 2
- Not diverse 6

DIRECTOR DASHBOARD Our directors bring diverse viewpoints and perspectives to our boardroom and exhibit a balance of tenure, skills, experiences, and backgrounds that we believe enhances the deliberation and decision-making processes of our Board of Directors and allows our Board of Directors to effectively fulfill its oversight function.



Our eight directors bring a balance of relevant skills and experience including those listed above.


U.S. Workforce Demographics

■ Professionals ■ Mid-level Managers ■ Executives / Senior Managers

GENDER



ETHNICITY




Totals

GENDER



ETHNICITY




Percentages may not total 100% due to rounding.


Attracting Diverse Talent

We are committed to attracting the best talent we can find, while providing our employees with challenging work in a fast-paced environment.

Growing Our Team



U.S. Employees



U.S. + OMM

Employee Engagement



Engagement score with 95% of employees participating in our annual 2021 “Employee Voice” survey.

New Hire Demographics


GENDER

	2021	2020
Female	31.7%	31.2%
Male	68.3%	68.8%



ETHNICITY

	2021	2020
White	60.5%	54.1%
Hispanic or Latino	7.0%	12.3%
Black or African Am.	8.2%	8.7%
Asian	20.2%	21.0%
All other ethnicities	4.1%	6.5%



Percentages may not total 100% due to rounding.

Sustainability Accounting Standards Board (SASB) Index

SASB is an independent nonprofit organization that sets standards to guide the disclosure of sustainability information by companies to their investors. The following Index maps Outset’s disclosures to certain SASB indicators. Data and information in this Report pertain to efforts in 2020 and 2021.

Topic	Accounting Metric(s)	Data/Response 2021 (2020)	SASB Code
Affordability & Pricing	Description of how price information for each product is disclosed to customers or to their agents	<p>Price information is initially communicated to customers through our quoting process. Once pricing is agreed upon, an Order Agreement is presented for final review and signature of acceptance by the customer. Through our quoting process, Outset’s commercial representatives utilize verbal and electronic communications to assess the customer’s short- and long-term needs, transparently determine pricing that is in line with customer needs and current market dynamics, and provide pricing that Outset believes will facilitate broad access to our proprietary technology. Price information is also included on customer invoices and billing statements.</p> <p>Consideration is given to all customers around contract length, minimum quantities to be purchased, rebates, and discounts, among other factors. In addition, many of our contracts will include a service option for capital equipment purchased. Our contracts with customers typically include general confidentiality clauses.</p>	HC-MS-240a.2
Product Safety	Number of recalls issued, total units recalled	Outset issued one Class II recall in January 2022. A total of 2,628 systems were included in the recall and updated at customer sites.	HC-MS-250a.1

Topic	Accounting Metric(s)	Data/Response 2021 (2020)	SASB Code
Product Safety	List of products listed in the FDA's MedWatch Safety Alerts for Human Medical Products database	None (None)	HC-MS-250a.2
Product Safety	Number of fatalities related to products as reported in the FDA Manufacturer and User Facility Device Experience database	Reported in the FDA Manufacturer and User Facility Device Experience (MAUDE) database, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm	HC-MS-250a.3
Product Safety	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	0 (0)	HC-MS-250a.4
Product Safety	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	In 2021 and 2020, Outset had no monetary losses due to legal proceedings associated with false marketing claims that were previously reported in the "Legal Proceedings" section of any of the Company's quarterly or annual reports filed with the Securities and Exchange Commission.	HC-MS-270a.1
Ethical Marketing	Description of code of ethics governing promotion of off-label use of products	Refer to Ethical Sales and Marketing in the Ethics and Compliance section, page 35 of our 2021 ESG Report .	HC-MS-270a.2

Topic	Accounting Metric(s)	Data/Response 2021 (2020)	SASB Code
Product Design & Lifecycle Management	Discussion of process to assess and manage environmental and human health considerations associated with chemicals in products, and meet demand for sustainable products	<p>Refer to the Simplicity, Savings, and Sustainability section, pages 11–18 of our 2021 ESG Report.</p> <p>Refer to the Environmental Sustainability section, pages 74–80 of our 2021 ESG Report.</p>	HC-MS-410a.1
Supply Chain Management	Percentage of (1) entity’s facilities and (2) Tier I suppliers’ facilities participating in third-party audit programs for manufacturing and product quality	<p>Refer to Supplier Audits in the Supply Chain Management section, page 66 of our 2021 ESG Report.</p> <p>(1) 100% of Outset’s certified manufacturing facilities participate in third-party (auditing organization) audits.</p> <p>(2) 100% of Outset’s Tier 1 supplier facilities participate in audit programs determined by Outset’s quality team, including third-party audit programs.</p>	HC-MS-430a.1
Supply Chain Management	Description of efforts to maintain traceability within the distribution chain	<p>Refer to Maintaining Traceability in the Supply Chain Management section, pages 66–67 of our 2021 ESG Report.</p> <p>Our Tablo systems are serialized, wifi enabled and can be tracked through our cloud connected data infrastructure. We also keep records and databases that provide backward traceability for components and forward traceability for the location of consoles.</p>	HC-MS-430a.2
Supply Chain Management	Description of the management of risks associated with the use of critical materials	Refer to Critical Materials in the Supply Chain Management section, page 67 of our 2021 ESG Report .	HC-MS-430a.3
Business Ethics	Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption	In 2021 and 2020, Outset had no monetary losses due to legal proceedings associated with bribery or corruption that were previously reported in the “Legal Proceedings” section of any of the Company’s quarterly or annual reports filed with the Securities and Exchange Commission.	HC-MS-510a.1
Business Ethics	Description of code of ethics governing interactions with healthcare professionals	<p>Refer to Interactions with Healthcare Professionals in the Ethics and Compliance section, page 34 of our 2021 ESG Report.</p> <p>Refer to page 10 of our Code of Business Conduct and Ethics.</p>	HC-MS-510a.2



Forward-Looking Statements

This report contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding current and future compliance and sustainability initiatives, anticipated environmental, social and governance policies and practices, expectations and estimates regarding market sizes and growth potential for Tablo, expectations regarding the continuing impact of the COVID-19 pandemic on us and our operations, and other plans, prospects, goals, initiatives, strategies, or future actions, events, or performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “intend,” “hope,” “potential,” “would,” “continue,” “ongoing” or the negative of these terms or similar expressions.

Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect our business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties, some of which cannot be predicted or quantified. These risks and uncertainties include: our future financial performance, including our expectations regarding our revenues, cost of revenues, operating expenses, gross margin and our ability to achieve and maintain future profitability; our ability to reduce manufacturing costs; our ability to attain market acceptance among providers and patients; our ability to manage our growth; our expansion into

the home hemodialysis market; our ability to ensure strong product performance and reliability; our relations with third-party suppliers, including contract manufacturers and single source suppliers; our ability to overcome manufacturing disruptions; the impact of COVID-19, natural or man-made disasters, and similar events, on our industry, business and results of operations; our ability to offer high-quality support for Tablo; our expectations of the sizes of the markets for Tablo; our ability to innovate and improve Tablo; our ability to effectively manage privacy, information and data security; concentration of our revenues in a single product and concentration of a large percentage of our revenues from a limited number of customers; our ability to compete effectively; our ability to accurately forecast customer demand and manage our inventory; our ability to ensure the proper training and use of Tablo; and our compliance with FDA and other regulations applicable to our products and business operations; as well as other risks and uncertainties described in the Risk Factors section of our public filings with the SEC, including our latest annual and quarterly reports. Forward-looking statements should be considered in light of these risks and uncertainties, and you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

This report also contains statistical data, estimates, and forecasts that are based on independent industry publications or other publicly available information, as well as other information based on our internal sources. This information involves many assumptions and limitations, and you are cautioned not to give undue weight to such

information. We have not independently verified the accuracy or completeness of the information contained in the industry publications and other publicly available information. Accordingly, we make no representations as to the accuracy or completeness of that information nor do we undertake to update such information after the date of this report.

Tablo is a registered trademark of Outset Medical, Inc. Other trademarks, trade names and service marks appearing in this report are the property of their respective owners.

.Outset

We welcome your feedback.
investors@outsetmedical.com

Outset Medical, Inc.
3052 Orchard Dr.
San Jose, CA 95134

outsetmedical.com

Published September 2022

©2022 Outset Medical, Inc. All rights reserved.